Varicella Zoster Virus
VZV reactivates following discontinuation of aciclovir prophylaxis for HSCT
Published in Medical Letter on the CDC and FDA, July 24th, 2005
According to a study from England, "Undergoing hemopoietic stem cell transplants (HSCT) are at high risk of varicella zoster virus (VZV) reactivation, with a significant incidence of dissemination.
"This study reports a retrospective analysis of 247 allogeneic HSCT recipients receiving anti-viral prophylaxis with low-dose oral aciclovir 400 mg/day, administered until immunosuppression was discontinued and the CD4+ cell count exceeded 200/mm3."
"Viral reactivation was successfully suppressed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Environmental Health
National exposure measurements to protect public health released - HIV/AIDS Therapy
Natural resistance of HIV type 2 to zidovudine described - Human Papillomavirus
Gene expression profile of cervical cells harboring HPV-16 reported - Listeriosis
Outbreak of listeriosis in U.S. traced to contaminated hot dogs - Pap Test
Physician recommendation improves likelihood of Pap testing - Acinetobacter Baumannii
Imipenem-resistant A. baumannii outbreak produced OXA-23 beta-lactamase - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
